UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): August 30, 2021

 

ORAMED PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

 

DELAWARE		001-35813		98-0376008
(State or Other Jurisdiction		(Commission		(IRS Employer
of Incorporation)		File Number)		Identification No.)

 

1185 Avenue of the Americas, Third Floor, New York, New York		10036
(Address of Principal Executive Offices)		(Zip Code)

 

844-967-2633

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading symbol		Name of each exchange on which registered
Common Stock, par value $0.012		ORMP		The Nasdaq Capital Market, Tel Aviv Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

On August 30, 2021, Oramed Pharmaceuticals Inc. (the "Company") held its 2021 Annual Meeting of Stockholders (the "2021 Annual Meeting"). The final voting results at the 2021 Annual Meeting are set forth below.

 

Proposal No. 1 — Re-election of Directors.

 

The stockholders re-elected the following directors of the Company to hold office until the next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal. The votes were as follows:

 

Director Name		For				Against				Abstain				Broker Non-Votes
Aviad Friedman			11,705,383				518,842				803,711				-
Dr. Miriam Kidron			11,453,419				776,749				797,768				-
Nadav Kidron			11,933,630				294,042				800,264				-
Dr. Arie Mayer			10,892,473				1,321,078				814,385				-
Kevin Rakin			10,155,935				2,056,527				815,474				-
Leonard Sank			11,834,896				367,860				825,180				-

 

Proposal No. 2 — Ratification of the Prior Approval of the 2019 Incentive Plan.

 

The stockholders ratified the prior approval of the Company’s 2019 Stock Incentive Plan. The votes were as follows:

 

For				Against				Abstain				Broker Non-Votes
	9,197,665				2,984,635				845,636				-

 

Proposal No. 3 — Ratification of the Prior Approval of the Amended and Restated 2019 Incentive Plan.

 

The stockholders ratified the prior approval of the Company’s Amended and Restated 2019 Stock Incentive Plan. The votes were as follows:

 

For				Against				Abstain				Broker Non-Votes
	9,183,977				2,978,838				865,121				-

 

Proposal No. 4 — Ratification of the Re-election of Aviad Friedman, Xiaoming Gao, Miriam Kidron, Nadav Kidron, Arie Mayer, Kevin Rakin and Leonard Sank as Directors of the Company.

 

The stockholders ratified the re-election of Aviad Friedman, Xiaoming Gao, Miriam Kidron, Nadav Kidron, Arie Mayer, Kevin Rakin and Leonard Sank as directors of the Company. The votes were as follows:

 

For				Against				Abstain				Broker Non-Votes
	11,517,909				687,325				822,702				-

 

Proposal No. 5 — Amendment to the Company’s Certificate of Incorporation to Effect a Staggered Board Structure.

 

The stockholders did not approve an amendment to the Company’s Certificate of Incorporation to effect a staggered board structure. The votes were as follows:

 

For				Against				Abstain				Broker Non-Votes
	8,157,257				4,085,313				785,366				-

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	ORAMED PHARMACEUTICALS INC.
	By:	/s/ Nadav Kidron
	Name:	Nadav Kidron
	Title:	President and CEO

 

August 31, 2021

 

 

2